All In Biotech

Drug Trial Radar · NCT01306461

Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations

A Phase III, Randomized, Double-masked 6-month Trial to Compare the Efficacy and Safety of the Preservative-free Fixed-dose Combination of Tafluprost and Timolol Eye Drops to Those of Tafluprost and Timolol Eye Drops Given Concomitantly in Patients With Open Angle Glaucoma or Ocular Hypertension

Last checked: Nov 20, 2026Latest source record: Jun 8, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 401 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

401

Actual

Start

Mar 2011

Primary completion

Apr 2012

Study completion May 2012

Sponsor

Lead sponsor
Santen OyIndustry
Sponsor type
Industry
First posted
Mar 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost and timolol (FDC) to concomitant administration of tafluprost and timolol. This study will enroll patients who have ocular hypertension or glaucoma. The study schedule includes seven visits to the study site and three stages: * washout of 5 days to 4 weeks depending on current glaucoma medication (if any) * 6-month study treatment period * 1-3 weeks post-study period

Conditions

  • Ocular Hypertension
  • Open-angle Glaucoma

Interventions

  • Timolol and TafluprostDrug

    Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily Treatment period 6 months

  • Fixed Dose Combination of tafluprost and timololDrug

    Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily. For masking purposes also: vehicle for timolol administered twice daily Treatment period 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the average diurnal intra-ocular pressure (IOP) at 6 monthsTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Debrecen, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.